Cargando…
Adverse drug event risk assessment by the virtual addition of COVID‐19 repurposed drugs to Medicare and commercially insured patients’ drug regimens: A drug safety simulation study
Drug safety is generally established from clinical trials, by pharmacovigilance programs and during observational phase IV safety studies according to drug intended or approved indications. The objective of this study was to estimate the risk of potential adverse drug events (ADEs) associated with d...
Autores principales: | Smith, Matt K., Bikmetov, Ravil, Al Rihani, Sweilem B., Deodhar, Malavika, Hafermann, Matthew, Dow, Pamela, Turgeon, Jacques, Michaud, Veronique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251090/ https://www.ncbi.nlm.nih.gov/pubmed/33786990 http://dx.doi.org/10.1111/cts.13025 |
Ejemplares similares
-
Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy
por: Al Rihani, Sweilem B., et al.
Publicado: (2020) -
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
por: Michaud, Veronique, et al.
Publicado: (2020) -
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models
por: Al Rihani, Sweilem B., et al.
Publicado: (2021) -
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
por: Deodhar, Malavika, et al.
Publicado: (2020) -
Disease-Induced Modulation of Drug Transporters at the Blood–Brain Barrier Level
por: Al Rihani, Sweilem B., et al.
Publicado: (2021)